NA Vaccine Institute

NA Vaccine Institute (NAVI) is a South Korean biotechnology company specializing in the development of next-generation vaccines and advanced adjuvant technologies. The company's core platform, Nex-Adjuvant, is designed to enhance the immune response and efficacy of various vaccine candidates, including those for COVID-19, respiratory syncytial virus (RSV), and shingles. NAVI focuses on addressing unmet medical needs in infectious diseases and oncology through the integration of recombinant protein technology and proprietary delivery systems. The institute actively collaborates with academic and industrial partners to accelerate the clinical translation of its pipeline programs.